2014
An updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder
Pizarro M, Fontenelle L, Paravidino D, Yücel M, Miguel E, de Menezes G. An updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder. Expert Opinion On Pharmacotherapy 2014, 15: 1391-1401. PMID: 24766145, DOI: 10.1517/14656566.2014.914493.Peer-Reviewed Original ResearchConceptsDouble-blind studyObsessive-compulsive disorderPathophysiology of OCDEfficacy of desvenlafaxineEfficacy of antidepressantsShort-term treatmentOlder antidepressantsSerotonergic effectsClinical trialsSerotonergic systemNew agentsAntidepressantsSystematic reviewReliable efficacyEfficacyUpdated reviewClomipramineOCD symptomsDisordersTreatmentCurrent studyReviewSSRIsDuloxetineMirtazapine
2011
A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder
Diniz J, Shavitt R, Fossaluza V, Koran L, de Bragança Pereira C, Miguel E. A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2011, 31: 763-768. PMID: 22020357, DOI: 10.1097/jcp.0b013e3182367aee.Peer-Reviewed Original ResearchConceptsY-BOCS scoresFluoxetine groupTreatment regimenSelective serotonin reuptake inhibitorsPlacebo-controlled trialSevere adverse eventsSerotonin reuptake inhibitorsMain outcome measuresObsessive-compulsive disorder patientsCompulsive Scale scoresYale-Brown ObsessiveFluoxetine monotherapyAdverse eventsReuptake inhibitorsObsessive-compulsive disorderPrimary diagnosisOutcome measuresDisorder patientsScale scoreFluoxetineMental disordersQuetiapinePatientsStatistical ManualClomipramine